SR49059

SR49059 is a non-peptide vasopressin antagonist drug that was discovered and developed by Sanofi-Aventis. It is primarily used in the research of vasopressin-related conditions and has been instrumental in the understanding of the role of vasopressin in the human body.

Overview

SR49059 is a potent and selective antagonist of the vasopressin V1a receptor. It has been used in the study of various vasopressin-related conditions, including hypertension, heart failure, and hyponatremia. The drug has also been used in the research of social behavior disorders, as vasopressin is known to influence social bonding and aggression.

Pharmacology

SR49059 acts by blocking the vasopressin V1a receptor, which is one of the three types of receptors that vasopressin can bind to. The V1a receptor is found in various parts of the body, including the vascular smooth muscle, myocardium, liver, and brain. By blocking this receptor, SR49059 can inhibit the various effects of vasopressin.

Clinical Use

While SR49059 is not currently approved for any specific medical use, it has been used in clinical trials for conditions such as Raynaud's disease and irritable bowel syndrome. However, the primary use of SR49059 is in research, where it has helped to elucidate the role of vasopressin in various physiological and pathological processes.

Side Effects

As with any drug, SR49059 can have side effects. These can include nausea, headache, and dizziness. However, these side effects are generally mild and transient.

See Also

• Vasopressin
• Vasopressin receptor
• Sanofi-Aventis

‎